Browse articles from EyeWorld.org related to gene therapy. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Enrollment complete in Phase 2 study for drug targeting endocannabinoid system for IOP lowering
➤ Dosing complete for Phase 1/2 trial evaluating a gene therapy for Stargardt disease
➤ Pre-Phase 3 Type B meeting held with FDA by company focused on retinitis pigmentosa
➤ Updates from several late-stage clinical trials
➤ New company launches to pioneer nonviral gene therapies
➤ ASCRS news and events
➤ FDA approves first IND for RNA exon editor
➤ SPA granted for Phase 3 trial of an intravitreal implant for wet AMD
➤ Study: retinal imaging helps predict risk of developing a host of diseases
➤ European Medicines Agency recommends rejection of pegcetacoplan for GA
➤ ASCRS news and events
➤ FDA agrees to special protocol assessment for AMD clinical trial
➤ Topline data from Phase 2 trial evaluating suprachoroidal wet AMD treatment
➤ First patient dosed in Phase 1 DME treatment study
➤ Study: new gene variants contributing to glaucoma susceptibility identified
➤ ASCRS news and events
➤ FDA approves updated femtosecond laser for refractive surgery
➤ Positive topline results from Phase 3, first-in-class dry eye disease studies
➤ Rare Disease Designation granted for investigational gene therapy
➤ Positive interim data for investigational Stargardt disease treatment
➤ First patient dosed in Phase 2 trial for DME treatment
➤ Research program established to investigate whole eye transplant
➤ ASCRS news and events
➤ Primary, secondary endpoints met in Phase 2 wet AMD trial
➤ Modifications made to investigational glaucoma treatment device
➤ Positive Phase 1/2 data from clinical trial for treatment of Leber congenital amaurosis
➤ Results from first-in-human study of siRNA treatment for AMD
➤ Possibility of a minimally invasive approach for treating AMD
➤ ASCRS news and events
➤ World’s first whole-eye transplant
➤ Regenerative Medicine Advanced Therapy designation for investigational therapy for Leber congenital amaurosis
➤ 48-month trial data for retinal prosthesis for patients with severe atrophic AMD
➤ First patient dosed in Phase 1/2 trial for Stargardt disease gene therapy
➤ Partnership to develop molecule targeting DME
➤ ASCRS news and events
A 14-year-old boy who had significant vision loss due to a rare genetic condition recently had his sight restored due to a first-of-its-kind topical gene therapy.
➤ Study: 1-year results with IOP-lowering implant
➤ Phase 2 study of investigational dry eye treatment nears enrollment target
➤ Study identifies antibody that could lead to retinitis pigmentosa treatment
➤ Gene therapy for inherited optic neuropathy approved for clinical trials
➤ ASCRS news and events
➤ FDA approves first treatment targeting Demodex
➤ Phase 1 study compares mechanical dry eye treatment to drop therapy
➤ Topical gene therapy for rare ocular surface condition
➤ Glaucoma drug licensed for commercialization in U.S.
➤ ASCRS news and events
➤ Study evaluates safety of office-based lens surgery
➤ FDA issues response to BLA for 8 mg aflibercept
➤ Pre-clinical data for non-viral gene therapy
➤ Non-human primate study of dry AMD therapy
➤ Expanded insurance coverage for MIGS procedures
➤ ASCRS news and events
